Photo: Depositphotos
May 25, 2025, 12:27
Nina Niu Sanford Reflects on EA2183 Trial Ending Due to Slow Accrual Over 5 Years
Nina Niu Sanford, Assistant Professor and Chief of Gastrointestinal Radiation Oncology at Harvard/Brigham and Women’s Hospital/Massachusetts General Hospital, shared a post on X:
“Sad to see EA2183 (systemic treatment +/- SBRT for oligomet esophagus/gastric ca) close due to slow accrual after enrolling 27 patients over 5+ years.
If the NCI/NIH wants to decrease research dependence on pharma/industry, need to better incentivize enrollment onto cooperative group trials.”
More posts featuring Nina Niu Sanford.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 25, 2025, 11:41
May 25, 2025, 11:24
May 25, 2025, 11:12
May 25, 2025, 10:51
May 25, 2025, 10:12
May 25, 2025, 09:48